Literature DB >> 26544944

The Molecular Taxonomy of Primary Prostate Cancer.

.   

Abstract

There is substantial heterogeneity among primary prostate cancers, evident in the spectrum of molecular abnormalities and its variable clinical course. As part of The Cancer Genome Atlas (TCGA), we present a comprehensive molecular analysis of 333 primary prostate carcinomas. Our results revealed a molecular taxonomy in which 74% of these tumors fell into one of seven subtypes defined by specific gene fusions (ERG, ETV1/4, and FLI1) or mutations (SPOP, FOXA1, and IDH1). Epigenetic profiles showed substantial heterogeneity, including an IDH1 mutant subset with a methylator phenotype. Androgen receptor (AR) activity varied widely and in a subtype-specific manner, with SPOP and FOXA1 mutant tumors having the highest levels of AR-induced transcripts. 25% of the prostate cancers had a presumed actionable lesion in the PI3K or MAPK signaling pathways, and DNA repair genes were inactivated in 19%. Our analysis reveals molecular heterogeneity among primary prostate cancers, as well as potentially actionable molecular defects.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26544944      PMCID: PMC4695400          DOI: 10.1016/j.cell.2015.10.025

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  90 in total

1.  Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer.

Authors:  Scott A Tomlins; Bharathi Laxman; Saravana M Dhanasekaran; Beth E Helgeson; Xuhong Cao; David S Morris; Anjana Menon; Xiaojun Jing; Qi Cao; Bo Han; Jindan Yu; Lei Wang; James E Montie; Mark A Rubin; Kenneth J Pienta; Diane Roulston; Rajal B Shah; Sooryanarayana Varambally; Rohit Mehra; Arul M Chinnaiyan
Journal:  Nature       Date:  2007-08-02       Impact factor: 49.962

2.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

Authors:  Scott A Tomlins; Daniel R Rhodes; Sven Perner; Saravana M Dhanasekaran; Rohit Mehra; Xiao-Wei Sun; Sooryanarayana Varambally; Xuhong Cao; Joelle Tchinda; Rainer Kuefer; Charles Lee; James E Montie; Rajal B Shah; Kenneth J Pienta; Mark A Rubin; Arul M Chinnaiyan
Journal:  Science       Date:  2005-10-28       Impact factor: 47.728

3.  Functional assays for classification of BRCA2 variants of uncertain significance.

Authors:  Daniel J Farrugia; Mukesh K Agarwal; Vernon S Pankratz; Amie M Deffenbaugh; Dmitry Pruss; Cynthia Frye; Linda Wadum; Kiley Johnson; Jennifer Mentlick; Sean V Tavtigian; David E Goldgar; Fergus J Couch
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

4.  Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators.

Authors:  Haley Hieronymus; Justin Lamb; Kenneth N Ross; Xiao P Peng; Cristina Clement; Anna Rodina; Maria Nieto; Jinyan Du; Kimberly Stegmaier; Srilakshmi M Raj; Katherine N Maloney; Jon Clardy; William C Hahn; Gabriela Chiosis; Todd R Golub
Journal:  Cancer Cell       Date:  2006-09-28       Impact factor: 31.743

5.  Increased prevalence of the BRCA2 polymorphic stop codon K3326X among individuals with familial pancreatic cancer.

Authors:  Sean T Martin; Hiroyuki Matsubayashi; Carmelle D Rogers; Juliet Philips; Fergus J Couch; Kieran Brune; Charles J Yeo; Scott E Kern; Ralph H Hruban; Michael Goggins
Journal:  Oncogene       Date:  2005-05-19       Impact factor: 9.867

6.  Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process.

Authors:  Uma R Chandran; Changqing Ma; Rajiv Dhir; Michelle Bisceglia; Maureen Lyons-Weiler; Wenjing Liang; George Michalopoulos; Michael Becich; Federico A Monzon
Journal:  BMC Cancer       Date:  2007-04-12       Impact factor: 4.430

7.  Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis.

Authors:  Jacques Lapointe; Chunde Li; Craig P Giacomini; Keyan Salari; Stephanie Huang; Pei Wang; Michelle Ferrari; Tina Hernandez-Boussard; James D Brooks; Jonathan R Pollack
Journal:  Cancer Res       Date:  2007-09-15       Impact factor: 12.701

8.  Evaluation of genetic patterns in different tumor areas of intermediate-grade prostatic adenocarcinomas by high-resolution genomic array analysis.

Authors:  Herman van Dekken; Pamela L Paris; Donna G Albertson; Janneke C Alers; Armann Andaya; David Kowbel; Theodorus H van der Kwast; Daniel Pinkel; Fritz H Schröder; Kees J Vissers; Mark F Wildhagen; Colin Collins
Journal:  Genes Chromosomes Cancer       Date:  2004-03       Impact factor: 5.006

9.  Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors.

Authors:  Pamela L Paris; Armann Andaya; Jane Fridlyand; Ajay N Jain; Vivian Weinberg; David Kowbel; John H Brebner; Jeff Simko; J E Vivienne Watson; Stas Volik; Donna G Albertson; Daniel Pinkel; Janneke C Alers; Theodorus H van der Kwast; Kees J Vissers; Fritz H Schroder; Mark F Wildhagen; Phillip G Febbo; Arul M Chinnaiyan; Kenneth J Pienta; Peter R Carroll; Mark A Rubin; Colin Collins; Herman van Dekken
Journal:  Hum Mol Genet       Date:  2004-05-11       Impact factor: 6.150

Review 10.  Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex.

Authors:  Hannelore V Heemers; Donald J Tindall
Journal:  Endocr Rev       Date:  2007-10-16       Impact factor: 19.871

View more
  1025 in total

1.  PDCD4 Is an Androgen-Repressed Tumor Suppressor that Regulates Prostate Cancer Growth and Castration Resistance.

Authors:  Kenji Zennami; Su Mi Choi; Ross Liao; Ying Li; Wikum Dinalankara; Luigi Marchionni; Fatema H Rafiqi; Akira Kurozumi; Koji Hatano; Shawn E Lupold
Journal:  Mol Cancer Res       Date:  2018-12-05       Impact factor: 5.852

2.  Targeting FOXA1-mediated repression of TGF-β signaling suppresses castration-resistant prostate cancer progression.

Authors:  Bing Song; Su-Hong Park; Jonathan C Zhao; Ka-Wing Fong; Shangze Li; Yongik Lee; Yeqing A Yang; Subhasree Sridhar; Xiaodong Lu; Sarki A Abdulkadir; Robert L Vessella; Colm Morrissey; Timothy M Kuzel; William Catalona; Ximing Yang; Jindan Yu
Journal:  J Clin Invest       Date:  2018-12-18       Impact factor: 14.808

3.  Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptor-Chromatin Interactions.

Authors:  Kush Dalal; Meixia Che; Nanette S Que; Aishwariya Sharma; Rendong Yang; Nada Lallous; Hendrik Borgmann; Deniz Ozistanbullu; Ronnie Tse; Fuqiang Ban; Huifang Li; Kevin J Tam; Mani Roshan-Moniri; Eric LeBlanc; Martin E Gleave; Daniel T Gewirth; Scott M Dehm; Artem Cherkasov; Paul S Rennie
Journal:  Mol Cancer Ther       Date:  2017-08-03       Impact factor: 6.261

4.  Biology and Clinical Implications of the 19q13 Aggressive Prostate Cancer Susceptibility Locus.

Authors:  Ping Gao; Ji-Han Xia; Csilla Sipeky; Xiao-Ming Dong; Qin Zhang; Yuehong Yang; Peng Zhang; Sara Pereira Cruz; Kai Zhang; Jing Zhu; Hang-Mao Lee; Sufyan Suleman; Nikolaos Giannareas; Song Liu; Teuvo L J Tammela; Anssi Auvinen; Xiaoyue Wang; Qilai Huang; Liguo Wang; Aki Manninen; Markku H Vaarala; Liang Wang; Johanna Schleutker; Gong-Hong Wei
Journal:  Cell       Date:  2018-07-19       Impact factor: 41.582

5.  Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function ERF Mutations.

Authors:  Franklin W Huang; Juan Miguel Mosquera; Andrea Garofalo; Coyin Oh; Maria Baco; Ali Amin-Mansour; Bokang Rabasha; Samira Bahl; Stephanie A Mullane; Brian D Robinson; Saud Aldubayan; Francesca Khani; Beerinder Karir; Eejung Kim; Jeremy Chimene-Weiss; Matan Hofree; Alessandro Romanel; Joseph R Osborne; Jong Wook Kim; Gissou Azabdaftari; Anna Woloszynska-Read; Karen Sfanos; Angelo M De Marzo; Francesca Demichelis; Stacey Gabriel; Eliezer M Van Allen; Jill Mesirov; Pablo Tamayo; Mark A Rubin; Isaac J Powell; Levi A Garraway
Journal:  Cancer Discov       Date:  2017-05-17       Impact factor: 39.397

Review 6.  A Case-Based Clinical Approach to the Investigation, Management and Screening of Families with BRCA2 Related Prostate Cancer.

Authors:  Bradley King; Jana McHugh; Katie Snape
Journal:  Appl Clin Genet       Date:  2021-05-20

7.  Genomic Heterogeneity Within Individual Prostate Cancer Foci Impacts Predictive Biomarkers of Targeted Therapy.

Authors:  David J VanderWeele; Richard Finney; Kotoe Katayama; Marc Gillard; Gladell Paner; Seiya Imoto; Rui Yamaguchi; David Wheeler; Justin Lack; Maggie Cam; Andrea Pontier; Yen Thi Minh Nguyen; Kazuhiro Maejima; Aya Sasaki-Oku; Kaoru Nakano; Hiroko Tanaka; Donald Vander Griend; Michiaki Kubo; Mark J Ratain; Satoru Miyano; Hidewaki Nakagawa
Journal:  Eur Urol Focus       Date:  2018-02-15

8.  Development of a stress response therapy targeting aggressive prostate cancer.

Authors:  Hao G Nguyen; Crystal S Conn; Yae Kye; Lingru Xue; Craig M Forester; Janet E Cowan; Andrew C Hsieh; John T Cunningham; Charles Truillet; Feven Tameire; Michael J Evans; Christopher P Evans; Joy C Yang; Byron Hann; Constantinos Koumenis; Peter Walter; Peter R Carroll; Davide Ruggero
Journal:  Sci Transl Med       Date:  2018-05-02       Impact factor: 17.956

9.  Lineage Plasticity in Cancer Progression and Treatment.

Authors:  Clémentine Le Magnen; Michael M Shen; Cory Abate-Shen
Journal:  Annu Rev Cancer Biol       Date:  2017-12-01

Review 10.  Cancer stem cells: Regulation programs, immunological properties and immunotherapy.

Authors:  Dingxiao Zhang; Dean G Tang; Kiera Rycaj
Journal:  Semin Cancer Biol       Date:  2018-05-09       Impact factor: 15.707

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.